NASDAQ / LIVE COMPANY INTELLIGENCE

Citius Oncology, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERCTOR
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / CTOR COVERAGE

What’s moving Citius Oncology, Inc. now

Current reporting with the operating signal separated from the noise.

01
Citius Oncology, Inc.: Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Citius Oncology, Inc.: Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

The story matters when it changes Citius Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

The story matters when it changes Citius Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

The story matters when it changes Citius Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

The story matters when it changes Citius Oncology, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

Investors are testing whether Citius Oncology, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
PRIMARY DOCUMENTS / SEC EDGAR

Latest CTOR filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-15 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2026-02-13 · Period 2025-12-31SEC ↗10-KAnnual financial reportFiled 2025-12-23 · Period 2025-09-30SEC ↗8-KMaterial company eventFiled 2026-06-01 · Period 2026-06-01SEC ↗8-KMaterial company eventFiled 2026-05-15 · Period 2026-05-15SEC ↗8-KMaterial company eventFiled 2026-05-06 · Period 2026-05-04SEC ↗DEF 14AProxy and shareholder meetingFiled 2025-09-26 · Period 2025-10-27SEC ↗EFFECTOfficial SEC filingFiled 2026-06-05SEC ↗
EARNINGS / QUARTERLY TRACKER

Citius Oncology, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.